<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04724967</url>
  </required_header>
  <id_info>
    <org_study_id>20201149</org_study_id>
    <nct_id>NCT04724967</nct_id>
  </id_info>
  <brief_title>CeraVe Diabetes Mellitus</brief_title>
  <official_title>Clinical Evaluation of CeraVe Hydrating Cleanser and Moisturizing Cream for the Improvement of Skin Condition in Patients With Diabetes Mellitus (DM) Related Skin Changes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Miami</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CeraVe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the CeraVe Diabetic Skin&#xD;
      Line for the improvement of skin condition in patients with diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2021</start_date>
  <completion_date type="Anticipated">February 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants reporting adverse events (AE)</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>As evaluated by treating physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of participants reporting adverse events (AE)</measure>
    <time_frame>Up to 33 days</time_frame>
    <description>As evaluated by treating physician</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician-assessed Global Aesthetic Improvement Scale (GAIS)</measure>
    <time_frame>up to 33 days</time_frame>
    <description>GAIS is rated from 3 (very much improved) to minus 3 (very much worse)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Diabetes Complications</condition>
  <arm_group>
    <arm_group_label>CeraVe Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this group will receive the CeraVe Hydrating Cleanser and Moisturizing Cream for 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CeraVe Hydrating Cleanser</intervention_name>
    <description>topical cleanser applied twice a day for 28 days</description>
    <arm_group_label>CeraVe Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CeraVe Moisturizing Cream</intervention_name>
    <description>topical cream applied twice a day for 28 days</description>
    <arm_group_label>CeraVe Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women between the ages of 18 and 75 years of age.&#xD;
&#xD;
          2. Willing to provide written informed consent.&#xD;
&#xD;
          3. A diagnosis of diabetes mellitus (DM).&#xD;
&#xD;
          4. DM-related skin changes classified into one or more of the following four categories:&#xD;
             i) skin lesions associated with DM; ii) infections; iii) cutaneous manifestations of&#xD;
             DM complications; iv) skin reaction to DM treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy, anaphylaxis or hypersensitivity to any of the ingredients in&#xD;
             CeraVe Hydrating Cleanser or Moisturizing Cream&#xD;
&#xD;
          2. History of allergic contact dermatitis secondary to cleansers or moisturizers.&#xD;
&#xD;
          3. Has a heightened immune response to common allergens, especially inhaled, topical or&#xD;
             food allergens (atopy).&#xD;
&#xD;
          4. Has any clinical manifestation in the treatment are(s) or other disorders that, in the&#xD;
             investigator's opinion, may affect assessments or the study products.&#xD;
&#xD;
          5. Inability to attend all study visits and follow treatment regimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Kirsner, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria V Muniz</last_name>
    <phone>305-689-2646</phone>
    <email>mmuniz@med.miami.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria V Muniz</last_name>
      <phone>305-689-2646</phone>
      <email>mmuniz@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Kirsner, MD/PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 21, 2021</study_first_submitted>
  <study_first_submitted_qc>January 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2021</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Robert S. Kirsner</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cutaneous complication of DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Complications</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dimenhydrinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

